In a pilot study, it was established that specific therapy by standard anti-hepatitis B virus (HBV) vaccination may be effective in reducing HBV replication and canceling the immune tolerance to hepatitis B surface antigen (HBsAg) particles in about 50% of persons with chronic active HBV replication. In the present study, the vaccine-induced immune responses were analyzed during an ongoing controlled multicenter vaccine trial. Vaccination elicited peripheral blood mononuclear cell proliferative responses specific for envelope antigen in 7 of 27 subjects given HBsAg. The responses induced by the vaccines were mediated by CD4 + T lymphocytes, and at least three different epitopes were recognized. HBV-specific CD4 + T lymphocytes produced high levels of interferon-g or -a and belonged to a T helper 1 subset. Reduction of serum HBV DNA in some of these persons suggests that induction of CD4 + T cell responses could be important in controlling viremia during vaccine therapy of chronic HBV carriers.
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Hepatitis B virus (HBV)-related hepatitis is a necroinflammatory liver disease of variable severity. Following initial infection, most persons develop acute hepatitis controlled by both humoral and cellular immune responses [1] . Nevertheless, 2%-20% of persons infected as adults and 95% of infected newborns in HBV-endemic areas fail to resolve the infection and subsequently become chronic carriers. Persistent infection is associated with a healthy carrier state in about one-third of persons and with chronic liver disease that can lead to the development of cirrhosis and hepatocellular carcinoma in twothirds. Persons with chronic active hepatitis have viral replication in hepatocytes that secrete large amounts of empty hepatitis B surface antigen (HBsAg) particles. HBsAg particles comprise three different viral envelope polypeptides (the small S, the middle preS2-S, and the large preS1-preS2-S proteins) anchored into a lipid bilayer. All three polypeptides contain the S domain. These particles persist in the serum and corresponding HBsAg-specific neutralizing antibodies (anti-HBs) remain undetectable by conventional techniques due to the formation of immune complexes [2] .
The antibody response to HBV envelope antigens is a T cell-dependent process that plays a critical role in viral clearance by complexing free virus particles. The cellular immune response contributes to the elimination of the virus but is also responsible for liver damage caused by the lytic activity of HBVspecific cytotoxic T lymphocytes on HBV-infected hepatocytes and by the production of inflammatory cytokines [3] . Chronic HBV infection is characterized by an inefficient T helper (Th) cell response to HBsAg and by a variable Th cell response to the nucleocapsid-related antigens, hepatitis core antigen (HBcAg), and hepatitis e antigen (HBeAg). Increased HBcAg/ HBeAg-specific Th cell responses are observed in persons with acute self-limited HBV-infection, whereas the HBsAg-specific Th cell response is much less vigorous in the same persons [1] . In contrast, the envelope-specific Th response is usually quite strong in a proportion of vaccine recipients who have been immunized with plasma-derived or recombinant HBsAg [4] [5] [6] [7] , suggesting that differences in antigen load or presentation may influence the strength of the HBs-specific T cell response.
Antiviral therapies like vidarabine monophosphate and interferon (IFN)-a inhibit HBV replication in only 20%-40% of persons with chronic active hepatitis. The use of nucleoside analogues such as lamivudine or penciclovir (currently in development) is impaired by selection of resistant mutated viruses [8, 9] . These difficulties and the immune-mediated pathology of HBV infection underline the need for new immune therapies for chronic HBV infection. Specific immunotherapeutic strat- egies have been designed to boost the weak HBV-specific immune response observed in chronic HBV carriers. To address this issue, we previously showed (by use of transgenic mice that constitutively express the HBsAg in the liver as a model of healthy chronic HBV carriers) that immunization can overcome functional tolerance to HBsAg by inducing a specific immune response [10, 11] . These findings provided the rationale for a pilot clinical study in which we demonstrated that specific vaccine therapy by standard anti-HBV vaccination reduced or circumvented HBV replication in 50% of chronic carriers [12, 13] . A controlled, multicenter study is under way to confirm the efficiency of HBV vaccine therapy. In the experiments described here, we investigated the lymphoproliferative and antibody responses developed during the vaccine therapy protocol in a subgroup of patients.
Materials and Methods

Subjects.
We enrolled 170 persons with biopsy-proven chronic hepatitis and active HBV replication as shown by the presence of HBV DNA in sera in a controlled study of vaccine therapy. None had prior anti-HBV therapy, immunosuppression, or infections associated with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis D virus (HDV). The subjects were randomized into three groups and received GenHevac B (PasteurMérieux, Sérums et Vaccins, Marnes la Coquette, France), Recombivax (Merck, West Point, PA), or no vaccine (control group). For 40 of the 170 HBsAg chronic carriers included in the therapeutic protocol, blood samples were available for a prospective analysis of the induction of immune responses: 17 in the GenHevac B vaccine group, 10 in the Recombivax group, and 13 in the control group. Mean ages and sex ratios were comparable for the three groups. Blood samples were collected at different times before and after vaccination, and peripheral blood mononuclear cells (PBMC) were stimulated in vitro with purified preS2/HBsAg and HBsAg corresponding to the vaccines.
Vaccines. Two different recombinant vaccines were used in this study. The GenHevac B vaccine is derived from transfected Chinese hamster ovary (CHO) mammalian cells and contains 22 nm of HBsAg particles, including the middle and small HBV envelope proteins (subtype ayw). The Recombivax vaccine contains HBsAg particles derived from yeast cells (Saccharomyces cerevisiae) and expresses only the small HBV envelope protein (subtype adw). Each 0.5-mL dose of vaccine contains 20 mg of HBsAg protein, with aluminum hydroxide as adjuvant.
Therapeutic schedule. The patients were first followed for у3 months, during which serum HBV DNA quantification and serologic tests were performed monthly (figure 1). No difference was observed at baseline in histologic or serologic parameters in the three groups. Experimental subjects were then given three standard injections of vaccine in the deltoid muscle at 1-month intervals, 1, 2, and 3 months after inclusion (M1, M2, M3), followed by 3 additional standard injections at 3-month intervals, 6, 9, and 12 months after inclusion (M6, M9, M12). Serologic tests were performed at different times during the protocol.
Postvaccination follow-up for evaluation of vaccine efficacy lasted у12 months. Efficacy was defined as a sustained loss or 50% prevaccination-level decrease of HBV DNA. Serum HBV DNA was detected by a liquid phase DNA-DNA hybridization (Murex procedure), as described previously [14] . Twelve months after inclusion, a standard antiviral therapy (5 MU of IFN-g subcutaneously 3 times/week for 6 months) was proposed to all the subjects in all groups (M12-M18). Vaccinated patients received an additional booster injection 24 months after inclusion (M24). The therapeutic schedule is summarized in figure 1 . Follow-up lasted 3 years.
PBMC preparation and separation of lymphocyte subsets. PBMC from 40 persons were prepared before vaccination (MϪ1, M0, or M1) and after vaccination (see figure 1 ) from fresh, heparinized blood by centrifugation on a ficoll-hypaque density gradient (UNI-SEP; NOVAmed, Jerusalem, Israel) and washed 3 times. B, T, CD8 ϩ , or CD4 ϩ cells were removed from PBMC by negative depletion by incubating the cells with mouse anti-human antibodies coated on magnetic beads (Dynal, Oslo). The purity of the subpopulations was monitored by immunolabeling with anti-CD4 ϩ , anti-CD8 ϩ , and anti-CD19 ϩ antibodies (Becton Dickinson, Grenoble, France). These procedures resulted in !2% contaminating cells as assessed by flow cytometry. PBMC or lymphocyte subsets were resuspended in RPMI 1640 (Gibco BRL, Cergy-Pontoise, France) supplemented with 10 mM HEPES, 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 5% human AB serum (complete medium).
Proliferation assay. PBMC or lymphocyte subsets at 1.5 ϫ 10 6 cells/mL in 0.2 mL of complete medium were cultured in 96-well round-bottom microplates in the presence or absence of HBsAg (0.1-3 mg/mL) or individual preS2 synthetic peptides (0.3-10 mg/ mL) in triplicate wells. After 3 days of culture at 37ЊC in an atmosphere of 5% CO 2 in air, the cells were labeled for 18 h with 1 mCi of [ 3 H]thymidine, and the DNA-incorporated radioactivity was measured by scintillation counting. Data were expressed either as mean counts per minute (cpm) of triplicate cultures or as the stimulation index (SI), calculated as the ratio between cpm obtained in the presence of antigen and cpm obtained without antigen.
HBV antigens and synthetic peptides. Recombinant ayw and adw preS2/HBsAg particles and ayw HBsAg particles were derived from transfected mammalian cells (CHO) [15] . Recombinant adw preS2/HBsAg [16] , adw HBsAg [17] , and ayw HBsAg (Medix Biotech, West Malling, UK) particles were derived from yeast cells (S. cerevisiae). Plasma-derived particles (ay or ad HEVAC B; PasteurMérieux, Sérums et Vaccins) purified from pooled sera of humans infected with HBV and containing virtually only the S domain (!1% preS2 protein) were provided by R. Vinas. Plasma-derived ayw HBsAg particles with preS1 and preS2 from an HBeAg-positive chronic HBV carrier were a gift of W. H. Gerlich. A recombinant preparation of HBcAg derived from bacterial extracts of Escherichia coli K12 corresponding to the full-length core antigen (ayw subtype) was a gift of D. Peterson [18] .
Three overlapping peptides, 25-26 residues long, corresponding to the complete sequence of the preS2-encoded polypeptide (subtype ayw), were synthesized (Neosystem, Strasbourg, France). These synthetic peptides are numbered by the amino acid position from the NH2 terminus of the preS1 domain of HBV ayw as follows: 109-134, 124-148, and 139-145.
ELISA. At various times before and after vaccination, antipreS2 antibodies were quantified in sera by ELISA. The preS2 peptide corresponding to amino acid sequences 109-134 was used on the solid phase. Peptide was coated onto microtiter plates at 1 mg/mL in carbonate buffer pH 9.6 for 1 h at 37ЊC. Wells were blocked with 1% bovine serum albumin (BSA) in PBS for 3 h at 37ЊC. Sera were diluted 10-fold in PBS supplemented with 1% BSA and 0.75 M NaCl and incubated for 90 min at 37ЊC. After 5 washes with PBST (PBS with 0.1% Tween), bound antibodies were detected with horseradish peroxidase-conjugated goat anti-human IgG (Calbiochem, La Jolla, CA) diluted in PBST containing 5% glycerol and 1% BSA. Reactions were developed using orthophenylenediamine as substrate, and the absorbance was measured at 450 nm. Results were expressed as optical density (OD) values. Samples were considered positive if ODs were more than twice the cutoff value ( ). OD ϭ 0.1 Cytokine assay. PBMC at 1.5 ϫ 10 6 cells/mL in 0.2 mL of complete medium were cultured in 96-well round-bottom microplates in the presence or absence of HBsAg (3 mg/mL) in triplicate wells. Culture supernatants were collected each day, and concentrations of interleukin (IL)-2, IL-10, and IFN-g were determined by commercial ELISA kits (Genzyme, Cambridge, MA). These assays were capable of detecting 5 pg/mL IL-2, IL-10, or IFN-g.
Results
Induction of PBMC proliferative responses to envelope antigens by vaccination of chronic HBV carriers.
Forty persons were available for proliferative response follow-up. PBMC were stimulated in vitro with purified preS2/HBsAg and HBsAg particles corresponding to the vaccines used in the protocol. The proliferative responses obtained before injection (M0), 3 months after the third injection (M6), and 3 months after the fifth injection (M12) are summarized in table 1. As previously observed [1] , no proliferative response specific to envelope antigens was observed for PBMC from chronic HBV carriers tested at different times before vaccination (MϪ1, M0, M1). In contrast, we showed that vaccination with GenHevac B induced a strong and sustained PBMC proliferative response specific to the purified antigen in this vaccine (preS2/HBsAg) in 4 of 17 GenHevac B vaccinees (patients G3, G4, G8, and G9). An additional patient (G10) showed a transient proliferative response at M12 (table 1) . Similarly, vaccination with Recombivax induced a strong and sustained PBMC proliferative response specific to HBsAg in 1 of 10 persons (patient R6). PBMC from another patient (R7) had transient proliferation at M9 (not shown) and M18 (table 1) . In contrast, none of the 13 control subjects exhibited any significant response to these two antigens. The overall prevalence of an HBsAg-specific proliferation was more frequent in vaccinated patients (29.4% in the GenHevac group, 20% in the Recombivax group, ) P ϭ .046 than in the control group.
Vaccination with GenHevac B induced a proliferative response specific to preS2/HBsAg after 1 injection (patient G9), 2 injections (patient G4), 3 injections (patients G3 and G8; figure 2A ), or 5 injections (patient G10; table 1). Vaccination with Recombivax induced a proliferative response specific to HBsAg after 2 injections (patient R6; figure 2B) or 4 injections (patient R7; not shown). Of interest, proliferative responses were observed only to the antigen corresponding to the vaccine (i.e., PBMC from patients who received the GenHevac B vaccine proliferated in vitro in the presence of preS2/HBsAg and not in the presence of yeast-derived HBsAg). The opposite was observed for patients who received the Recombivax vaccine, indicating that the composition, serotype, and/or origin of these recombinant antigens were determinants for the stimulation of PBMC.
Proliferative responses were also evaluated after an additional 6 months (M18), during which most of the subjects (35 of 40) were treated with IFN-a. Vaccine-induced proliferative responses were maintained during IFN-a treatment in the 3 GenHevac B patients with strong proliferative responses (patients G3, G4, and G8) and in the fourth without IFN-a treatment (patient G9). The Recombivax patient (R6) with strong proliferative responses stopped the vaccine therapy before the end of the protocol (M9) and did not receive IFN-a. Proliferative responses were sustained for patients G3, G4, G8, G9, and R6, respectively, until 36, 24, 30, 18, and 18 months after inclusion (last follow-up). IFN-a treatment alone did not induce envelope antigen-specific proliferative responses in control subjects, and the additional IFN-a treatment did not induce such a response in persons who did not respond to the vaccine (table 1) .
We also tested HBcAg proliferative responses. Strong and transient HBcAg proliferative responses were observed before or after vaccination in some chronic HBV carriers from all three groups (not shown), indicating that this response, in contrast to the HBsAg-specific response, was present in untreated chronic carriers. Nevertheless, some subjects who demonstrated vaccine-induced HBsAg proliferative responses also had strong and transient HBcAg proliferative responses.
Virologic evolution of persons with vaccine-induced PBMC proliferative response to HBsAg. To evaluate the correlation of vaccine-induced proliferative responses to inhibition of HBV replication in chronic hepatitis B patients, serum HBV DNA and HBV serology were determined before and during the vaccination protocol. Vaccine responders were defined as persons with a sustained loss of HBV DNA (titers !10 pg/mL) or a decrease of 150% of prevaccination titers.
HBsAg-specific proliferation was noted for 7 of the 27 vac- was considered significant. SI 1 3 cinated subjects but in none of 13 controls. Prevaccine HBV DNA titers were not different between persons who had proliferative responses ( pg/mL) and those with no 1137 ‫ע‬ 2273 proliferation ( pg/mL). HBV DNA negation at M6 2032 ‫ע‬ 1859 and M12 was more frequently obtained in subjects with proliferation (28.6% and 57.1%, respectively) than in those without proliferation (6.7% and 20%, respectively), but this difference did not reach statistical significance. At M18, the percentages of HBV DNA negativity were 57.1% and 33.3% for persons with and without proliferative responses, respectively (not significant). Most of the patients, however, were given IFN-a, precluding definitive conclusions about the long-term efficacy of the vaccine per se.
Prevaccination data and 6-to 12-month data after the first injection are shown in table 2 for the 7 persons with vaccineinduced proliferative responses. Among 5 subjects with HBsAgspecific proliferative responses who received GenHevac B vaccine, serum HBV DNA became undetectable in 2 (G3 and G9) and decreased by 150% of the prevaccination titers in patient G8, whose HBV replication stopped after 1 additional injection (M12) and 3 months of IFN-a treatment (not shown). Two other persons cleared HBV DNA without displaying proliferative responses. Serum HBV DNA titers for patient G4 were still high, despite the presence of anti-HBs antibodies at the beginning of the protocol, as well as in subject G10 (transient proliferative responses). No subject cleared serum HBsAg, but 1 (G9) developed anti-HBs antibodies a few months after the HBV DNA elimination. Five patients (including G3, G8, and 
NOTE. Hepatitis B virus (HBV) serology and serum HBV DNA quantification are shown before (M0) and after vaccination (M6, M12). Seroconversion and sustained loss or 50% prevaccination level of HBV DNA are underlined. Hepatitis e antigen (HBeAg), hepatitis B surface antigen (HBsAg), anti-HBe, and anti-HBs antibodies were determined by commercial kits. Ag, antigen; s, surface.
a Patient R6 stopped immunotherapy before end of vaccination protocol.
G9) who were initially HBeAg positive developed anti-HBe antibodies simultaneously with HBV DNA and serum HBeAg clearance. This clearance persisted during and after the 6-month IFN-a treatment, since HBV DNA and HBeAg were undetectable in the sera of patients G3, G8, and G9, tested, respectively, at 36, 24, and 18 months after inclusion. Among persons receiving the Recombivax vaccine, serum HBV DNA decreased to a very low level in subjects R6 and R7 with HBsAg-specific proliferative responses and became negative in another person without detectable cellular response. HBV DNA remained persistently negative during and after the IFN-a treatment (M18 and M24). Subject R7, who had a weak proliferative response at M9 (after 4 vaccine injections), showed anti-HBe and an absence of HBeAg before and during the vaccination protocol. Patient R6 did not clear HBeAg even during the IFN-g treatment. Neither person cleared HBsAg or developed anti-HBs antibodies.
Of the 13 controls, 12 remained HBV DNA-positive at M6 and 10 at M12. No anti-HBe spontaneous seroconversion was observed at M6, but one was noted at M12. None of the controls cleared HBsAg during the follow-up period.
In summary, a persistent antiviral effect was clearly observed for 5 of the 7 patients with vaccine-induced envelope-specific proliferative responses, since HBV DNA titers became negative or substantially decreased.
Detection of anti-preS2 antibodies after vaccination. We also analyzed the humoral response during the vaccine therapy protocol by measuring anti-preS2 antibodies in plasma before and after the subjects were vaccinated. For that we used the 109-134 synthetic peptide corresponding to a linear B epitope [19] . Before vaccination (M0), anti-preS2 antibodies were either not detectable or at low levels in the plasma of chronic HBV carriers, except for 1 subject in the Recombivax group ( figure 3B) . The anti-preS2 antibody response was either induced or greatly enhanced after vaccination (M6, M9, M12) for 5 of 17 subjects given the preS2-containing GenHevac B vaccine ( figure 3A ). This response was enhanced by additional vaccine injections ( figure 3A) . Four of the 5 persons with anti-preS2 antibodies had a vaccine-induced preS2/HBsAg proliferative response, indicating a correlation between a preS2/HBsAg-proliferative response and an anti-preS2 antibody response. Anti-preS2 antibodies were also induced or greatly enhanced after vaccination in 2 of 10 subjects given Recombivax vaccine (figure 3B). Nevertheless, this response could not be related to HBsAg-specific proliferative response and probably corresponded to activation of preS2-specific B cells already present in the patients. Finally, none of the 13 tested controls showed an anti-preS2 antibody response during this protocol ( figure 3C ). These results indicate that anti-preS2 antibody production by activated preS2-specific B cells is regulated by S-specific and preS2-specific T helper cells induced by vaccination with GenHevac B. Anti-preS2 antibody production observed after Recombivax vaccination in persons without HBsAg-specific proliferative response could be regulated by HBcAg-specific Th cells, as HBcAg proliferation was observed in these patients.
The proliferative response specific to GenHevac B is mediated by CD4
ϩ T lymphocytes. To determine the PBMC subpopulation involved in GenHevac B-induced proliferative response, we carried out negative depletion experiments. In a first set of experiments, CD19 ϩ B cells or CD8 ϩ and CD4 ϩ T cells were depleted from PBMC by use of magnetic beads coated with corresponding specific antibodies. Undepleted or depleted cells were cultured in the presence of preS2/HBsAg. Depletion of B lymphocytes had no effect on the PBMC proliferative response, whereas depletion of T lymphocytes completely abolished it (not shown). These results suggest that the proliferative response is mediated by T lymphocytes and that B cells are not required as the antigen-presenting cells in vitro.
To further characterize the T cell subset involved in proliferative responses, similar experiments were performed with CD4 ϩ and CD8 ϩ cell depletion. As shown in figure 4 for 3 patients who received GenHevac B injections, depletion of 
CD8
ϩ T lymphocytes from PBMC did not inhibit the proliferative response to preS2/HBsAg, whereas depletion of CD4 ϩ T lymphocytes completely abrogated it, indicating that the response to preS2/HBsAg is mediated by CD4 ϩ T lymphocytes. Moreover, in these experiments, we compared the proliferative response of depleted cells to CHO-derived preS2/HBsAg of two different subtypes and showed that the CD4 ϩ T cells responded equally well to restimulation with HBsAg of ayw or adw subtype.
The CD4 ϩ T cell response to GenHevac B is specific for preS2 
and S domains.
In order to analyze the fine specificity of the response, we tested different antigens derived from CHO cells or from human plasma and three overlapping synthetic peptides corresponding to the entire ayw preS2 sequence for their ability to stimulate PBMC. As shown in table 3, PBMC from subjects with GenHevac B-induced proliferative response were efficiently stimulated by HBsAg particles either containing or lacking preS2, indicating that this response was directed against at least the S domain in all subjects. This response is independent of the subtype of this antigen. HIV gp120 antigen derived from CHO was inefficient, indicating that the responses were specific for HBV envelope antigens. Moreover, preS1/preS2 HBsAg particles purified from human plasma were able to stimulate PBMC from patient G4 displaying strong proliferative responses. Using synthetic peptides, we observed that two peptides corresponding to the N-terminal domain (109-134) and to the C-terminal domain (139-163) of preS2 also stimulated PBMC from 2 patients, indicating that the response was directed against preS2 domains in some of them. Patients without a preS2/HBsAg-specific proliferative response did not exhibit significant response to these preS2 peptides. These results show that the proliferative response obtained was specific for at least three epitopes of the HBV envelope middle protein.
T lymphocyte activation is dependent of the nature of the antigen used for restimulation. To understand why proliferative responses were observed only after stimulation with the related immunogen, we compared stimulation of PBMC with HBsAg of different origins. We used HBsAg purified from plasma of chronic HBV carriers and recombinant HBsAg obtained from genetically modified mammalian (CHO) or yeast cells. Generally and as shown in figure 5A , PBMC from GenHevac B-immunized persons proliferated in the presence of CHOderived antigens but not in the presence of S. cerevisiae-derived antigens. PBMC from subject G8 were an exception: repro- ducible proliferative responses occurred in the presence of ayw HBsAg derived from S. cerevisiae cells ( ). In contrast, SI ϭ 4.6 PBMC from a Recombivax-immunized patient (figure 5B) proliferated in the presence of yeast-derived antigens but not in the presence of CHO-derived antigens. Responses observed cannot be attributed to CHO-or yeast-contaminating proteins, since vaccine preparations were highly purified. In addition, no proliferative response was observed in the presence of irrelevant antigens, recombinant HIV-1 envelope glycoprotein produced and purified from CHO, or recombinant human superoxidedismutase from S. cerevisiae (not shown). Moreover, a significant proliferative response was detected in the presence of plasma-derived HBsAg with patient G4, which showed a strong proliferative response towards recombinant envelope antigens, indicating that this response is specific for HBV envelope. These results suggest that the differences in observed responses after antigenic restimulation are not due to protein composition or to the serotype of the antigen but rather to antigen specificities linked to the origin of cells producing the antigen. These specificities may be related to different maturation events, such as glycosylation, or to different constitutive lipids.
Cytokine release of HBsAg-specific PBMC. The antigendriven cytokine secretion pattern of in vitro restimulated T cells was analyzed next. A Th1-like pattern characterized by the secretion of IFN-g or IL-2 in the absence of IL-10 was detected in PBMC from vaccinated persons who showed proliferative responses to HBsAg (table 4) . IFN-g and IL-2 secretion was detected only after restimulation with antigens inducing positive proliferative responses. IL-2, IL-10, or IFN-g was not detected in PBMC from vaccinated patients who lacked detectable proliferative responses to HBsAg (not shown).
Discussion
Persons with chronic active hepatitis show viral replication and high levels of circulating HBsAg particles. Even so, no or very weak HBV-specific T cell responses are detectable, unlike in acute infection, where these responses are associated with HBV clearance [1, 3] . In order to boost a preexisting weak HBVspecific T cell response or to induce a response de novo, we used a reinforced specific vaccination protocol with HBV recombinant envelope. We observed that, despite high levels of circulating envelope antigen, vaccination with HBsAg particles induced envelope-specific CD4 ϩ T cell proliferative responses and allowed bypass of the nonresponsiveness observed in persons with chronic HBV. Nevertheless, these responses were obtained only for some vaccinated patients. In fact, during vaccination of healthy subjects, HBsAg-specific T cell proliferative responses have been observed only in some persons termed "high responders." Intermediate responders mount only a protective level of HBsAg-specific antibodies, and nonresponders do not develop anti-HBs antibodies [6, [20] [21] [22] [23] . The reason for this disparity between cellular and humoral immune responses in vaccine responders is unknown. A clear relationship between major histocompatibility complex type and the human immune response to HBsAg was not found [21, 24, 25] . Nevertheless, HBsAg-specific CD4 ϩ T cells seem to be present in the circulation of intermediate responders, but at limited concentrations [4] .
Depletion of B lymphocytes did not impair the proliferative response observed after restimulation in vitro (not shown), indicating that the monocyte-macrophage lineage was responsible for processing and presentation of antigens to T cells. Proliferative responses were observed in 5 persons after vaccination with GenHevac B containing the preS2 domain and in 2 persons given the Recombivax vaccine containing only the S domain of HBV envelope proteins. After vaccination with GenHevac B, the responses were specific for preS2 and S domains. In 2 different patients, we showed (using synthetic peptides) that at least two epitopes are recognized in the preS2 domain. The response is independent of ayw or adw serotypes of antigens, suggesting that the Th epitopes recognized are present in conserved regions of the protein. PreS regions increase the immunogenicity of HBsAg in several strains of inbred mice [26] . PreS-specific T cells have been seen after vaccination of healthy subjects, sometimes with higher frequency than for S domain [6, 7, 22] . By adding targets to the immune system, the presence of preS2 domain in the vaccine may explain why there were more responders to the GenHevac B vaccine.
The cellular origin of recombinant envelope proteins appears to constrain the in vitro antigen recognition by activated T lymphocytes since cross-reactivity between plasma-, CHO-, or S. cerevisiae-derived antigens was observed only when strong proliferative responses were detected. Nevertheless, proliferative responses could be detected by using preS2 peptides or plasma-derived HBsAg particles but not with control antigens prepared from CHO and yeast cells, indicating that these responses are HBV-specific. These constraints may be related to different maturation events, such as glycosylation, or to different constitutive lipids. Glycosylation of envelope antigens in CHO and yeast cells differs in type, number of sites, and carbohydrate composition [15, 27] . In the Recombivax vaccine, the small HBV envelope protein is present only in its unglycosylated form, whereas the GenHevac B vaccine contains the small and the middle protein in both glycosylated and unglycosylated forms. Glycopeptides can elicit glycopeptide-specific T cell responses, and recognition by T cells is dependent on the chemical structure of the glycan [28, 29] . In contrast, carbohydrates within an epitope can function as hindering structures that limit antigen immunogenicity for T lymphocytes [30] . Moreover, HBsAg particles are composed of proteins inserted into cellular lipid membranes. Constitutive membrane lipids differ between mammalian and yeast cells [31] . Differences in lipid or sugar composition may lead to antigen capture by different antigen-presenting cells using specialized mechanisms for antigen uptake. Different mechanisms of uptake as macropinocytosis and mannose-or fucose-specific receptors determine the intracellular compartment to which antigens are delivered and may lead to the generation of different T cell epitopes [32] . Moreover, differences in composition between recombinant antigen vaccines and bona fide viral antigens could explain the nonresponsiveness of some chronic carriers by affecting antigen capture or antigen processing by antigen-presenting cells.
The CD4 ϩ T cell response showed a Th1-like profile characterized by secretion of IFN-g in the absence of IL-10 production, as has been described for healthy persons after vaccination [20] . IFN-g has a wide spectrum of activities, including control of HBV gene expression [33] and induction of cytotoxic T cells [34] .
Specific antibodies directed to the preS2 domain were induced after vaccination with GenHevac B, confirming that vaccination can restore the specific B cell immune response in persons with chronic hepatitis B whose preS2-antibodies are generally not detectable [35, 36] . The efficacy of vaccine therapy will be fully evaluated only by analyzing results from the 170 patients in the multicenter trial. Nevertheless, the decrease in serum HBV DNA in 5 of 7 persons with proliferative responses suggests that the restoration of an envelope-specific CD4 ϩ T cell response could be critical in HBV replication control.
HBcAg-specific CD4 ϩ T cell responses were associated with control of viremia during acute infection or during IFN-a treatment of chronic HBV patients [37] [38] [39] . Specific CD4 ϩ T cell proliferative responses were associated with clinical improvement or control of viremia in HCV, HDV, and HIV models [40] [41] [42] . In an HIV-1 model, strong HIV-1-specific CD4 ϩ proliferative responses were present in persons in whom HIV-1 viremia was controlled and were induced in early infected patients in whom HIV-1 viremia was controlled after antiviral therapy [42] . Specific CD4 ϩ T cells are required to sustain CD8 ϩ T cells during chronic viral infections [43] , suggesting that therapeutic vaccination could enhance both CD4 ϩ and CD8 ϩ virusspecific T cells [44] . The mechanisms involved in the control of viral infections may be related to enhanced cytotoxic T lymphocyte precursor activity, increase of humoral immune responses, or increased production of antiviral cytokines by CD4 ϩ T cells.
In conclusion, vaccination during persistent HBV infection enabled some persons to overcome the unresponsiveness observed towards circulating HBsAg particles and HBV by inducing an envelope-specific CD4 ϩ T cell response and an anti-preS2-specific B cell response. The antiviral effect observed in some of the subjects with vaccine-induced proliferative response suggests that benefit could be derived from the induction of HBV-specific CD4 ϩ T cells in persons chronically infected with HBV.
